| You are here: Home: BCU 4|2004: Maria Theodoulou, MD: Select publications
Select publications
Batist G etal. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54. Abstract
Citron M etal. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. Abstract
O'ShaughnessyJ. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology 2002:16(10 Suppl 12);17-22. Abstract
Slamon D etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001:344;783-92. Abstract
Theodoulou Metal. TLC D99 and Herceptin is safe in advanced breast cancer: final cardiac safety and efficacy analysis. ASCO AnnualMeeting 2002 ;Abstract 216.
Trigo J et al. Cardiac safety and activity of a phase I study of 3-weekly myocet in combination with weekly herceptin and paclitaxel in HER2-positive locally advanced or metastatic breast cancer. ASCO Annual Meeting 2002;Abstract 242.
Vogel C etal. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
